<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02465814</url>
  </required_header>
  <id_info>
    <org_study_id>17541</org_study_id>
    <secondary_id>2014-004221-41</secondary_id>
    <nct_id>NCT02465814</nct_id>
  </id_info>
  <brief_title>Assess Safety and Efficacy of Vilaprisan in Patients With Uterine Fibroids</brief_title>
  <acronym>ASTEROID 2</acronym>
  <official_title>A Randomized, Parallel-group, Double-blind Placebo-controlled and Open Label Active Controlled, Multi-center Study to Assess the Efficacy and Safety of Vilaprisan in Patients With Uterine Fibroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is performed to assess the efficacy of Vilaprisan (BAY1002670) in patients with
      uterine fibroids compared to placebo and ulipristal. It is also aimed to evaluate the safety
      of vilaprisan in subjects with uterine fibroids. Further, data on population pharmacokinetic
      (PK)/ pharmacodynamic (PD) relationship for vilaprisan in subjects with uterine fibroids will
      be supplemented.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amenorrhea (yes/no)</measure>
    <time_frame>From day 7 to day 84 of treatment.</time_frame>
    <description>Defined as no scheduled or unscheduled bleeding/spotting after end of the initial bleeding episode until the end of the respective treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of bleeding days</measure>
    <time_frame>Up to 32 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of controlled bleeding</measure>
    <time_frame>Up to 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in volume of largest fibroid from baseline to end of treatment.</measure>
    <time_frame>Baseline and up to 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endometrial histology</measure>
    <time_frame>Baseline and up to 40 weeks</time_frame>
    <description>(Frequency of the following categories: benign endometrium, endometrial hyperplasia, malignant neoplasm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endometrial thickness measured by transvaginal ultrasound.</measure>
    <time_frame>Baseline and up to 40 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Leiomyoma</condition>
  <arm_group>
    <arm_group_label>Arm 1 - BAY1002670 + BAY1002670</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vilaprisan (BAY1002670) 2 mg once daily (12 weeks), Vilaprisan 2 mg once daily (12 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 - Placebo + BAY1002670</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo once daily (12 weeks), Vilaprisan 2 mg once daily (12 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 - BAY1002670 + BAY1002670</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vilaprisan 2 mg once daily (12 weeks), treatment break, Vilaprisan 2 mg once daily (12 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4 - Placebo+BAY1002670</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo once daily (12 weeks), treatment break, Vilaprisan 2 mg once daily(12 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5 - Ulipristal + Ulipristal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ulipristal 5 mg once daily (12 weeks), treatment break, Ulipristal 5 mg once daily (12 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 6- Placebo + Ulipristal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo once daily (12 weeks), treatment break, Ulipristal 5 mg once daily (12 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 7- Ulipristal + Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ulipristal 5 mg once daily (12 weeks), treatment break, Placebo once daily (12 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vilaprisan (BAY1002670)</intervention_name>
    <description>Vilaprisan 2 mg (12 weeks), Vilaprisan 2 mg (12 weeks)</description>
    <arm_group_label>Arm 1 - BAY1002670 + BAY1002670</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vilaprisan (BAY1002670</intervention_name>
    <description>Placebo (12 weeks),Vilaprisan (12 weeks)</description>
    <arm_group_label>Arm 2 - Placebo + BAY1002670</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vilaprisan (BAY1002670</intervention_name>
    <description>Vilaprisan 2 mg (12 weeks), treatment break, Vilaprisan 2 mg (12 weeks)</description>
    <arm_group_label>Arm 3 - BAY1002670 + BAY1002670</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vilaprisan (BAY1002670)</intervention_name>
    <description>Placebo (12 weeks), treatment break, Vilaprisan 2 mg (12 weeks)</description>
    <arm_group_label>Arm 4 - Placebo+BAY1002670</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ulipristal</intervention_name>
    <description>Ulipristal 5 mg (12 weeks), treatment break, Ulipristal 5 mg (12 weeks)</description>
    <arm_group_label>Arm 5 - Ulipristal + Ulipristal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ulipristal</intervention_name>
    <description>Placebo (12 weeks), treatment break, Ulipristal 5 mg (12 weeks)</description>
    <arm_group_label>Arm 6- Placebo + Ulipristal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ulipristal</intervention_name>
    <description>Ulipristal (12 weeks), treatment break, Placebo (12 weeks)</description>
    <arm_group_label>Arm 7- Ulipristal + Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women, 18 to 50 years of age at the time of screening

          -  Diagnosis of uterine fibroid(s) documented by transvaginal or abdominal ultrasound at
             screening with at least 1 fibroid with largest diameter &gt;/=3.0 cm

          -  Heavy menstrual bleeding (HMB) &gt;80 mL documented by menstrual pictogram (MP) in a
             bleeding episode during the screening period. Women who did not suffer from perceived
             HMB during the 3 months prior to Visit 1 due to any effective medical treatment, e.g.
             with a hormonal contraceptive, are not considered appropriate candidates and should
             not undergo further screening procedures. Women suffering from perceived HMB despite
             medical treatment, e.g. with a hormonal contraceptive, are appropriate candidates for
             further screening, if rules on stopping prior medication are followed. Heavy menstrual
             bleeding /HMB) &gt; 80 mL should be documented within 10 consecutive days.

          -  Good general health (except for findings related to uterine fibroids) as proven by
             medical history, physical and gynecological examinations, and laboratory test results

          -  Normal or clinically insignificant cervical smear not requiring further follow-up.
             Human papilloma virus (HPV) testing in subjects with atypical squamous cells of
             undetermined significance (ASCUS) can be used as an adjunctive test. Subjects with
             ASCUS can be included if they are negative for high-risk HPV strains.

          -  An endometrial biopsy performed during the screening period, without significant
             histological disorder such as endometrial hyperplasia (including simple hyperplasia)
             or other significant endometrial pathology.

          -  Use of an acceptable nonhormonal method of contraception (i.e. either male condom,
             cap, diaphragm or sponge, each in combination with spermicide) starting at the
             bleeding episode following the screening visit 1 (Visit 1) until the end of the study.
             This is not required if safe contraception is achieved by a permanent method, such as
             bilateral fallopian tube blockage of the subject or vasectomy of the partner(s).

        Exclusion Criteria:

          -  Pregnancy or lactation (less than 3 months since delivery, abortion, or lactation
             before start of treatment)

          -  Uterine fibroid with largest diameter &gt;10.0 cm

          -  Hypersensitivity to any ingredient of the study drugs

          -  Hemoglobin values &lt;/= 6 g/dL or any condition requiring immediate blood transfusion
             (subjects with hemoglobin values &lt;/=10.9 g/dL will be offered iron supplementation).

          -  Any diseases or conditions that can compromise the function of the body systems and
             could result in altered absorption, excessive accumulation, impaired metabolism, or
             altered excretion of the study drug

          -  Any diseases or conditions that might interfere with the conduct of the study or the
             interpretation of the results

          -  Abuse of alcohol, drugs, or medicines (e.g. laxatives)

          -  Use of other treatments that might interfere with the conduct of the study or the
             interpretation of the results

          -  Undiagnosed abnormal genital bleeding.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Villach</city>
        <state>Kärnten</state>
        <zip>9500</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Graz</city>
        <state>Steiermark</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Innsbruck</city>
        <state>Tirol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tienen</city>
        <state>Vlaams Brabant</state>
        <zip>3300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles - Brussel</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <zip>1504</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stara Zagora</city>
        <zip>6000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ceske Budejovice</city>
        <zip>37001</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olomouc</city>
        <zip>772 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pisek</city>
        <zip>39701</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plzen</city>
        <zip>30708</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 2</city>
        <zip>120 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 8</city>
        <zip>180 81</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha</city>
        <zip>13000</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Helsinki</city>
        <zip>00610</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pori</city>
        <zip>28500</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Turku</city>
        <zip>20100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bernburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>06406</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Blankenburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>38889</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Debrecen</city>
        <zip>4024</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szentes</city>
        <zip>H-6600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Modena</city>
        <state>Emilia-Romagna</state>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cagliari</city>
        <state>Sardegna</state>
        <zip>09042</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Catania</city>
        <state>Sicilia</state>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vilnius</city>
        <zip>LT-05263</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vilnius</city>
        <zip>LT-08217</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vilnius</city>
        <zip>LT-10207</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Almere</city>
        <zip>1315 RA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heerlen</city>
        <zip>6419 PC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zwolle</city>
        <zip>8025 AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fredrikstad</city>
        <zip>1605</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lørenskog</city>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nesttun</city>
        <zip>5221</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stavanger</city>
        <zip>4011</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bialystok</city>
        <zip>15- 224</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <zip>90-602</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <zip>20-093</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <zip>20-632</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lisboa</city>
        <zip>1449-005</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto</city>
        <zip>4202-451</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aravaca</city>
        <state>Madrid</state>
        <zip>28023</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <zip>118 83</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Umeå</city>
        <zip>90185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Harrow</city>
        <state>London</state>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>N19 5NF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portsmouth</city>
        <zip>PO6 3LY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2015</study_first_submitted>
  <study_first_submitted_qc>June 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2015</study_first_posted>
  <last_update_submitted>November 21, 2016</last_update_submitted>
  <last_update_submitted_qc>November 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uterine fibroids</keyword>
  <keyword>Heavy Menstrual Bleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

